Keith W. Pratz, MD, on AML: Venetoclax, Azacitidine, and Disease Response

June 17, 2021 By The ASCO Post Staff

Keith W. Pratz, MD, of the University of Pennsylvania, discusses the outcomes of patients with acute myeloid leukemia who took part in the VIALE-A trial and were treated with venetoclax and azacitidine. The patients had achieved both composite complete remission and measurable residual disease of < 10-3 (Abstract S137).

Related Content